학술논문

Dectin-1 Controls TSLP-Induced Th2 Response by Regulating STAT3, STAT6, and p50-RelB Activities in Dendritic Cells
Document Type
article
Source
Subject
Biomedical and Clinical Sciences
Immunology
Vaccine Related
Prevention
Emerging Infectious Diseases
Clinical Research
Biodefense
Aetiology
2.1 Biological and endogenous factors
Inflammatory and immune system
Adult
Allergens
Animals
Antigens
Dermatophagoides
Antigens
Plant
Case-Control Studies
Cytokines
Dendritic Cells
Dermatophagoides farinae
Disease Models
Animal
Female
HEK293 Cells
Humans
Hypersensitivity
Immunity
Lectins
C-Type
Macaca mulatta
Male
Middle Aged
NF-kappa B p50 Subunit
OX40 Ligand
Plant Proteins
STAT3 Transcription Factor
STAT6 Transcription Factor
Signal Transduction
Th2 Cells
Transcription Factor RelB
beta-Glucans
Thymic Stromal Lymphopoietin
Dectin-1
TSLP
OX40L
dendritic cells
STAT3
STAT6
Th2 cells
allergy
Medical Microbiology
Biochemistry and cell biology
Genetics
Language
Abstract
The epithelium-associated cytokine thymic stromal lymphopoietin (TSLP) can induce OX40L and CCL17 expression by myeloid dendritic cells (mDCs), which contributes to aberrant Th2-type immune responses. Herein, we report that such TSLP-induced Th2-type immune response can be effectively controlled by Dectin-1, a C-type lectin receptor expressed by mDCs. Dectin-1 stimulation induced STAT3 activation and decreased the transcriptional activity of p50-RelB, both of which resulted in reduced OX40L expression on TSLP-activated mDCs. Dectin-1 stimulation also suppressed TSLP-induced STAT6 activation, resulting in decreased expression of the Th2 chemoattractant CCL17. We further demonstrated that Dectin-1 activation was capable of suppressing ragweed allergen (Amb a 1)-specific Th2-type T cell response in allergy patients ex vivo and house dust mite allergen (Der p 1)-specific IgE response in non-human primates in vivo. Collectively, this study provides a molecular explanation of Dectin-1-mediated suppression of Th2-type inflammatory responses and suggests Dectin-1 as a target for controlling Th2-type inflammation.